BG108131A - Използване на gabaa инверсни агонисти в комбинация с частични агонисти на никотинов рецептор, естроген, селективни модулатори на естроген или витамин е за лечение на когнитивни увреждания - Google Patents
Използване на gabaa инверсни агонисти в комбинация с частични агонисти на никотинов рецептор, естроген, селективни модулатори на естроген или витамин е за лечение на когнитивни уврежданияInfo
- Publication number
- BG108131A BG108131A BG108131A BG10813103A BG108131A BG 108131 A BG108131 A BG 108131A BG 108131 A BG108131 A BG 108131A BG 10813103 A BG10813103 A BG 10813103A BG 108131 A BG108131 A BG 108131A
- Authority
- BG
- Bulgaria
- Prior art keywords
- vitamin
- treatment
- estrogen
- receptor partial
- nicotine receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27256601P | 2001-03-01 | 2001-03-01 | |
| PCT/IB2002/000515 WO2002069948A1 (en) | 2001-03-01 | 2002-02-20 | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108131A true BG108131A (bg) | 2004-09-30 |
Family
ID=23040351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108131A BG108131A (bg) | 2001-03-01 | 2003-08-25 | Използване на gabaa инверсни агонисти в комбинация с частични агонисти на никотинов рецептор, естроген, селективни модулатори на естроген или витамин е за лечение на когнитивни увреждания |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20020193360A1 (bg) |
| EP (1) | EP1363606A1 (bg) |
| JP (1) | JP2004527500A (bg) |
| KR (1) | KR20030076717A (bg) |
| CN (1) | CN1494422A (bg) |
| AP (1) | AP2002002465A0 (bg) |
| AR (1) | AR033425A1 (bg) |
| BG (1) | BG108131A (bg) |
| BR (1) | BR0207802A (bg) |
| CA (1) | CA2439581A1 (bg) |
| CR (1) | CR7059A (bg) |
| CZ (1) | CZ20032338A3 (bg) |
| DO (1) | DOP2002000345A (bg) |
| EA (1) | EA200300854A1 (bg) |
| EC (1) | ECSP034759A (bg) |
| EE (1) | EE200300422A (bg) |
| GT (1) | GT200200039A (bg) |
| HU (1) | HUP0303448A3 (bg) |
| IL (1) | IL157465A0 (bg) |
| IS (1) | IS6905A (bg) |
| MA (1) | MA26999A1 (bg) |
| MX (1) | MXPA03007834A (bg) |
| NO (1) | NO20033821L (bg) |
| NZ (1) | NZ527397A (bg) |
| OA (1) | OA12554A (bg) |
| PA (1) | PA8540701A1 (bg) |
| PE (1) | PE20020927A1 (bg) |
| PL (1) | PL364081A1 (bg) |
| SK (1) | SK10752003A3 (bg) |
| TN (1) | TNSN02018A1 (bg) |
| UY (1) | UY27188A1 (bg) |
| WO (1) | WO2002069948A1 (bg) |
| ZA (1) | ZA200306193B (bg) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| WO2005000806A2 (en) | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| EP1924712B1 (en) * | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| CA2686155C (en) * | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| AU2013202426B2 (en) * | 2006-10-16 | 2015-08-06 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| CA2666219C (en) | 2006-10-16 | 2017-02-07 | Bionomics Limited | Novel anxiolytic compounds |
| US9974832B2 (en) | 2007-02-09 | 2018-05-22 | Cognitive Research Enterprises, Inc. | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| CA2709774C (en) * | 2008-05-22 | 2012-10-02 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
| US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
| US10206921B2 (en) * | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| WO2010151524A1 (en) * | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
| JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
| WO2012116415A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| WO2012116410A1 (en) * | 2011-03-02 | 2012-09-07 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| AU2012253237B2 (en) | 2011-05-12 | 2015-09-24 | Bionomics Limited | Methods for preparing naphthyridines |
| CA2934553C (en) | 2013-12-20 | 2023-10-31 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| IL256354B (en) | 2015-06-19 | 2022-09-01 | Agenebio Inc | History of benzodiazepines, preparations and their use for the treatment of cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112020026062B1 (pt) | 2018-06-19 | 2023-04-04 | Agenebio, Inc | Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson |
| CN116008442B (zh) * | 2023-03-27 | 2023-06-30 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的合成中间体的杂质检测方法 |
| CN116077459B (zh) * | 2023-04-10 | 2023-07-07 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的胶囊剂及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502548A (en) * | 1997-08-25 | 2002-06-28 | Neurogen Corp | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| WO2000071528A1 (en) * | 1999-05-25 | 2000-11-30 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
-
2002
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Application Discontinuation
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Application Discontinuation
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
-
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 BG BG108131A patent/BG108131A/bg unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108131A (bg) | Използване на gabaa инверсни агонисти в комбинация с частични агонисти на никотинов рецептор, естроген, селективни модулатори на естроген или витамин е за лечение на когнитивни увреждания | |
| WO2001085145A8 (en) | A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| BR0200283A (pt) | Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios | |
| CO5370677A1 (es) | Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina | |
| ATE463247T1 (de) | Bupropion metaboliten zur behandlung von angstzuständen | |
| ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
| HUP0302476A2 (hu) | Acetilkolinészteráz inhibitorok és GABAA inverz agonisták együttes alkalmazása értelmi rendellenességek kezelésére és gyógyszerkészítmények előállítására | |
| MA27863A1 (fr) | Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur | |
| PA8597301A1 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| TW200631956A (en) | Azabenzoxazoles for the treatment of CNS disorders | |
| MY124786A (en) | Bis-arylsulfones | |
| HK1081880A1 (en) | Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
| TR200000149T2 (tr) | Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar | |
| AP2002002420A0 (en) | Fused pyrrolecarboxamides: gaba brain receptor ligands. | |
| CO5390077A1 (es) | Nuevos derivados heterociclicos de urea y su uso como ligantes receptores d3 de dopamina | |
| BR0104345A (pt) | Tratamento combinado para a depressão e ansiedade | |
| ATE261443T1 (de) | 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen | |
| BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
| DK1192161T3 (da) | Chromeno[4,3,2-de]isoquinoliner som kraftige dopaminreceptorligander | |
| ES2176642T3 (es) | Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales. | |
| ATE369354T1 (de) | Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems | |
| UA34141A (uk) | Спосіб отримання лікарського препарату з ембріонального мозку | |
| CL2003002467A1 (es) | Compuestos derivados de bencilpiperazina y bencilpiperidina; metodo de preparacion; composicion farmaceutica; y uso de los compuestos para los trastornos del snc tales como enfermedad de parkinson, agresion, trastornos de ansiedad, autismo, depresion |